October 26, 2015.
Writing for the pharmaviews.eu blog on Friday, Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), called for a global “charter” to ensure that new antibiotics will be administered in a controlled manner and at affordable prices.
The new approach must "include de-linking revenues from selling, at least outside the richer countries in Europe and North America", wrote Bergström. "What I mean is that pharma companies should not have an incentive to sell as much as they can. Somehow they have to be rewarded differently, such as through an advanced purchase commitment (such as real or virtual stock-piling), or with transferable rights, reflecting the voucher system that is prevalent in the US."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.